PrEP

Collaborative efforts between patients, physicians, pharmacists, and other essential personnel can further promote the effectiveness of PrEP regimens.

Brad McElya, PharmD, director of specialty health solutions at Walgreens, discusses the critical role pharmacists play in providing HIV prevention drugs in communities across America.

Truvada is a medicine people at risk for HIV should take to prevent infection with the virus from various ways, such as sex or injection drug use.

A generic TDF/FTC costs as low as $30 per month, compared with about $1800 per month for branded TAF/FTC

Despite the fact that 98% of the survey respondents said they were aware of PrEP, less than 25% were currently taking it.

The sNDA seeks to expand the label of cabotegravir and rilipivirine to include dosing of every 2 months for the treatment of HIV-1 infection in virologically suppressed adults (HIV-1 RNA less than 50 copies per milliliter) on a stable regimen.

New, long-term data from open-label extensions of a pair of phase 3 studies of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets showed the sustained efficacy and safety profile of the treatment.

Geographic shifts in the HIV epidemic, racial disparities, and the complexities of the medical system all present obstacles to prevention and treatment services.

Researchers, advocates, and other stakeholders are urging for care to be expanded to overcome barriers in high-risk populations to address the HIV epidemic, as part of a series published in The Lancet HIV in the USA Series.

In order to eradicate HIV, the researchers said increasing health coverage will be essential. Without that, HIV will continue to spread, and individuals will be unaware of their status.

Patients with HIV who were hospitalized with COVID-19 were found to have high proportions of HIV virologic control on antiretroviral therapy.

At the virtual 2020 ASHP Midyear Clinical Meeting and Exhibition, Elyse Tung, PharmD, BCACP, discussed key counseling points for pharmacists to address with patients when prescribing and managing PrEP.

Additional non-oral options could provide more manageable forms of PrEP treatment for patients, potentially increasing global uptake of PrEP in the future.

Further, the study showed cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis (PrEP).

Further, the study showed cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis (PrEP).

This activity is supported by an educational grant from Janssen Therapeutics, division of Janssen Products, LP.

Top news of the week from Pharmacy Times.

Less than 10% of the people who should be taking pre-exposure prophylaxis for HIV are taking the medications.

Insurance companies are currently investigating the option of modifying which medications they will cover for HIV pre-exposure prophylaxis (PrEP) therapy, with broad implications for patient access.

Learn how retail or specialty pharmacy distribution can affect access to these important drugs.

Although the use of preexposure prophylaxis against HIV has increased across the United States in recent years, the rise in costs across the health care system has yet to be fully catalogued.

Men at particular risk for HIV are very likely to consistently take preventative medication during vacations when their odds of contracting the virus are higher, according to a study conducted by researchers at the University of Pittsburgh.

The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) study has played a key role in helping the health care industry look closer at the disproportionate risk of comorbidities, such as chronic liver and kidney disease, physical function impairment and frailty, premature reproductive aging, and cancer in patients with HIV.

Regional and state access assistance, improved research and collaboration, and individualized options for patients are key factors in adherence to PrEP.

The new report intends to change the practices in the HIV/coinfections research community so that women, providers, and policy makers can make evidence-based decisions regarding the use of medications during pregnancy.

Event-driven PrEP is initiated 2-24 hours ahead of sexual activity, but the most common method of HIV PrEP is a daily oral pill.

Small, automated financial incentives improved retention in care and viral suppression among adults with HIV starting antiretroviral therapy.

Results were announced at the virtual 23rd International AIDS Conference.

In developing countries with overcrowded hospitals, community pharmacies can relive burden, help patients adhere to their regimen, thus offering a viable alternative to patients who need to maintain their medication and keep stable.

PrEP-AP is intended to lower out-of-pocket costs for both uninsured and insured people who are eligible for PrEP services such as laboratory tests.